Access to hepatitis C treatment in Cameroon: comparison of a simplified test and treat strategy to a standard strategy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202507792256411

Enrollment

576

Registered

2025-07-23

Start date

2025-09-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C

Interventions

Standard Strategy

ACCESS Strategy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Persons of both genders aged 21 years or older; - Anti-HCV positive; - Living in the study area; - Agreeing to participate in the trial and signing the informed consent form.

Exclusion criteria

Exclusion criteria: - Participation in a previous study on HCV treatment - Previous sofosbuvir treatment - HBsAg positive or indeterminate; - Pregnancy test positive ; - Life-threatening condition ; - Impairment of the person making it difficult, if not impossible, for them to participate in the trial or to understand the information given to them.

Design outcomes

Primary

Measure	Time frame
% of anti-HCV positive patients at enrolment who were correctly managed (classified as follows): Success if ‘baseline HCV RNA negative and informed of this result’ or ‘baseline HCV RNA positive, treated and HCV RNA negative 24 weeks after start of treatment’ Failure in the other situations including ‘baseline HCV RNA not tested’, ‘baseline HCV RNA negative but not informed of this result’, ‘baseline HCV RNA positive and untreated’, ‘baseline HCV RNA positive, treated and HCV RNA positive or not tested 24 weeks after start of treatment’, and ‘missing data’	—

Measure

Time frame

% of anti-HCV positive patients at enrolment who were correctly managed (classified as follows): Success if ‘baseline HCV RNA negative and informed of this result’ or ‘baseline HCV RNA positive, treated and HCV RNA negative 24 weeks after start of treatment’ Failure in the other situations including ‘baseline HCV RNA not tested’, ‘baseline HCV RNA negative but not informed of this result’, ‘baseline HCV RNA positive and untreated’, ‘baseline HCV RNA positive, treated and HCV RNA positive or not tested 24 weeks after start of treatment’, and ‘missing data’

—

Secondary

Measure	Time frame
Cumulative of % of anti-HCV positive patients who had an HCV RNA test; % of anti-HCV positive patients who were HCV RNA positive; % of anti-HCV positive patients who were aware of HCV RNA status; % of HCV RNA positive patients who started direct-acting antiviral (DAA) treatment; time between HCV RNA test and treatment start; % of HCV RNA positive patients who completed the treatment; % of HCV RNA positive patients who were cured;Improvements in health-related quality of life and fatigue reported in SF12 scale and Fatigue scale;Total cost of the two strategies over the trial period and over the long term, in terms of disability adjusted life years, and quality-adjusted life years	—

Measure

Time frame

Cumulative of % of anti-HCV positive patients who had an HCV RNA test; % of anti-HCV positive patients who were HCV RNA positive; % of anti-HCV positive patients who were aware of HCV RNA status; % of HCV RNA positive patients who started direct-acting antiviral (DAA) treatment; time between HCV RNA test and treatment start; % of HCV RNA positive patients who completed the treatment; % of HCV RNA positive patients who were cured;Improvements in health-related quality of life and fatigue reported in SF12 scale and Fatigue scale;Total cost of the two strategies over the trial period and over the long term, in terms of disability adjusted life years, and quality-adjusted life years

—

Countries

Cameroon

Contacts

Public ContactTounes Saidi

ANRS MIE

tounes.saidi@inserm.fr+33153946034

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026